Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs.[2] Headquartered in
Mainz,
Germany, the company operates in 14 countries.[3]
History
Filling Schott glass ampoules with medications (1932)Schott & Gen. advertisement for borosilicate glass vials (1923)
In 1887,
Otto Schott developed
borosilicate glass for technical applications. Starting in 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials.[4]
Schott Pharma was established as a standalone company in 2022 through a
carve-out from
Schott AG, a manufacturer of specialty glass and glass-ceramics.[5]
In September 2023, Schott Pharma went public on the
Frankfurt Stock Exchange. With a value of €935 million, the
IPO was the largest of the year in Germany.[6][7] In December 2023, Schott Pharma was included in the
SDAX.[8]
Company Profile
The company is headquartered in Mainz and operates in 16 locations across 14 countries.[9]
The company is listed on the Frankfurt Stock Exchange's SDAX. The majority of its shares are held by Schott AG (as of 2023: 77%).[7]
Schott Pharma develops and manufactures drug containment solutions and delivery systems for injectable drugs, which it supplies to companies in the
biotechnology and
pharmaceutical industries.[10]
Its business is divided into two divisions:
Drug Containment Solutions: pharmaceutical vials, cartridges, and glass ampoules
Drug Delivery Systems: prefillable glass syringes and syringes made from
Cyclic olefin copolymers (COC), suitable for deep-cold medications.[11]